.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
Boehringer Ingelheim
Baxter
Cerilliant
Johnson and Johnson
Medtronic
Queensland Health
Daiichi Sankyo
Merck

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203565

« Back to Dashboard
NDA 203565 describes INJECTAFER, which is a drug marketed by Luitpold Pharms Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the INJECTAFER profile page.

The generic ingredient in INJECTAFER is ferric carboxymaltose. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric carboxymaltose profile page.

Summary for 203565

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4

Pharmacology for NDA: 203565

Ingredient-typeIron
Mechanism of ActionPhosphate Chelating Activity

Suppliers and Packaging for NDA: 203565

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS 203565 NDA American Regent, Inc. 0517-0650 0517-0650-01 1 VIAL, SINGLE-DOSE in 1 BOX (0517-0650-01) > 15 mL in 1 VIAL, SINGLE-DOSE
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS 203565 NDA American Regent, Inc. 0517-0650 0517-0650-02 2 VIAL, SINGLE-DOSE in 1 BOX (0517-0650-02) > 15 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength750MG IRON/15ML (50MG IRON/ML)
Approval Date:Jul 25, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 25, 2016
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Feb 5, 2024Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Feb 13, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Cipla
Daiichi Sankyo
Mallinckrodt
Johnson and Johnson
Citi
Covington
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot